Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 1b/2a Study to Evaluate the Safety and Tolerability of Oral SVG103 (Paxalisib) in Adults With Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

NCT07287202 is registered in ClinicalTrials.gov with Sovargen as lead sponsor.

NCT NCT07287202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07287202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 1b/2a Study to Evaluate the Safety and Tolerability of Oral SVG103 (Paxalisib) in Adults With Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
Lead sponsor
Sovargen
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 14, 2026
Completion date
March 31, 2027
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

focal cortical dysplasia, hemimegalencephaly, tuberous sclerosis complex (tsc)